PENTEC vs QUANTEC/HyTEC: late effects in children vs adults
TL;DRNo effect size reported in source; organ-by-organ synthesis finds pediatric late-effect risk similar, greater, or less than adult, depending on tissue and age.
QUANTECHyTECPENTEC
Adult QUANTEC/HyTEC constraints do not transfer uniformly to children: neurocognition, cerebrovascular and breast-lactation risks run greater in children, ovary less, lung perhaps slightly less. Within the pediatric range, younger children carry greater hearing and neurocognitive risk, so age at RT should modify how a constraint is read when planning brain or posterior fossa fields.
Adult QUANTEC/HyTEC constraints do not transfer uniformly: neurocognition, cerebrovascular and breast-lactation risks run greater in children, ovary less. Younger children carry greater hearing and neurocognitive risk, so age at RT should modify how brain and posterior fossa constraints are read.
6 details
Narrative comparison of PENTEC with the adult QUANTEC and HyTEC efforts across content, oversight, support, scope and literature-review method, followed by organ-specific pediatric findings.
Child vs adult risk is similar for brain necrosis, optic apparatus, parotid and liver; greater for neurocognition, cerebrovascular and breast lactation; less for ovary; perhaps slightly less for lung. Maldevelopment of musculoskeletal tissue, teeth, breast and reproductive organs is relevant primarily only in children.
| Organ / endpoint | Children vs adults | Younger vs older children |
|---|---|---|
| Brain, necrosis | Similar | Not stated |
| Optic apparatus | Similar | Not stated |
| Parotid | Similar | Not stated |
| Liver | Similar | Not stated |
| Brain, neurocognition | Greater | Greater in younger |
| Cerebrovascular | Greater | Not stated |
| Breast, lactation | Greater | Not stated |
| Lung | Perhaps slightly less | Not stated |
| Ovary | Less | Lesser in younger |
| Hearing | Not stated | Greater in younger |
| Thyroid | Not stated | Lesser in younger |
| Musculoskeletal, teeth, breast, reproductive maldevelopment | Relevant primarily only in children | Not stated |
QUANTEC and HyTEC remain the adult reference for conventional and hypofractionated constraints; PENTEC is the pediatric counterpart, and this paper is the first framing of where the two sets diverge by organ.
Comparisons are confounded by treatment paradigm (cancer type, dose, fields, chemo), and the optimal age model (continuous vs groupings) is unresolved.
Age and developmental status modify risk in organ-specific directions, so a single age cutoff for applying adult or pediatric constraints is not supported. The authors state further work is needed to define how age shapes risk.
- Should age enter NTCP models as continuous or developmental groupings?
- Do child vs adult differences persist after adjusting for fields and chemo?
📚 Sources · 📄 1 paper
Abstract
The longer read
The useful frame here is that age is not a uniform risk multiplier. A common clinical shortcut treats children as categorically more radiosensitive and applies adult QUANTEC or HyTEC constraints with an informal safety margin. This synthesis argues against that heuristic in both directions. For some endpoints (brain necrosis, optic apparatus, parotid, liver) the pediatric and adult risk appear similar, so a blanket tightening of constraints may cost target coverage without buying toxicity reduction. For others (neurocognition, cerebrovascular injury, breast function for lactation) risk is greater in children, and adult-derived thresholds would understate harm. For the ovary the direction reverses, with less risk in children and lesser risk again in younger children within the pediatric range.
The within-pediatric gradient matters as much as the child-adult contrast. Younger children carry greater risk for hearing loss and neurocognitive decline, while younger age is associated with lesser risk for ovary and thyroid. A planner treating a toddler and an adolescent with the same posterior fossa field is effectively working with two different constraint sets, and the paper is candid that the field has not settled whether age should enter NTCP models as a continuous variable or as developmental bands.
The central methodological caveat is confounding, and the authors name it directly. Children and adults receiving RT differ in histology, prescription dose, field design and concurrent chemotherapy. A pediatric medulloblastoma survivor and an adult glioma pt differ in far more than age, so an apparent age effect on neurocognition could partly reflect craniospinal fields or chemotherapy exposure rather than developmental sensitivity alone. That should temper confidence in the direction calls where the paper hedges (lung, 'perhaps slightly less') and in any attempt to read the comparisons as causal.
The abstract offers directions only, without dose-volume thresholds or NTCP magnitudes, so the value of this piece is as a map of where to consult the organ-specific PENTEC reports rather than as a source of numbers. Its practical message for planning is that adult constraint tables are a reasonable starting point for some organs and a misleading one for others, and that the pediatric developmental endpoints (musculoskeletal growth, dentition, breast and reproductive development) have no adult analogue at all. What would make this framing wrong is if the observed differences dissolve once treatment paradigm is adjusted for; until age-stratified data with harmonized exposure exist, the comparisons should be read as directional and hypothesis-generating.